Twist Bioscience appoints drug discovery leader Melissa Starovasnik to board

Twist Bioscience Corp

Dr. Starovasnik appointed to board effective Aug 5, 2021; will receive $40k cash retainer (pro rata) and $340k in equity vesting over 3 years.
She spent nearly 30 years at Genentech, most recently as Senior Scientific Advisor, leading protein therapeutics discovery.
Kevin Yankton appointed principal accounting officer; previously Chief Accounting Officer at Varex Imaging; James Thorburn remains CFO.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Melissa Starovasnik

Director

TWST · Twist Bioscience Corp

Effective: 2021-08-05
Filed: August 9, 2021, 7:59 PM ET

On August 5, 2021, the Board of Directors (the “ Board ”) of Twist Bioscience Corporation (the “ Company ”) elected Dr. Melissa Starovasnik to the Board, effective immediately.

Appointed

Kevin Yankton

principal accounting officer

TWST · Twist Bioscience Corp

Effective: 2021-08-05
Filed: August 9, 2021, 7:59 PM ET

On August 5, 2021, Board appointed Kevin Yankton, the Company’s Chief Accounting Officer, as principal accounting officer, effective August 5, 2021.

Role change

James Thorburn

principal accounting officer

TWST · Twist Bioscience Corp

Effective: 2021-08-05
Successor: Kevin Yankton
Filed: August 9, 2021, 7:59 PM ET

James Thorburn, the Company’s Chief Financial Officer, previously served as principal accounting officer and will continue to serve as Chief Financial Officer and principal financial officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Melissa Starovasnik was elected as Director at Twist Bioscience Corp.

Action: elected
Role: Director

Exact text from the filing

On August 5, 2021, the Board of Directors (the “ Board ”) of Twist Bioscience Corporation (the “ Company ”) elected Dr. Melissa Starovasnik to the Board, effective immediately.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Kevin Yankton was appointed as principal accounting officer at Twist Bioscience Corp.

Action: appointed
Role: principal accounting officer

Exact text from the filing

On August 5, 2021, Board appointed Kevin Yankton, the Company’s Chief Accounting Officer, as principal accounting officer, effective August 5, 2021.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.8

James Thorburn changed role as principal accounting officer at Twist Bioscience Corp.

Action: stepped down
Role: principal accounting officer

Exact text from the filing

James Thorburn, the Company’s Chief Financial Officer, previously served as principal accounting officer and will continue to serve as Chief Financial Officer and principal financial officer.

View on SEC.gov

Twist Bioscience Corp filing history →

Source: SEC EDGAR

accession 0001104659-21-102285

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.